The pharmacokinetics of fluconazole are expected to be different in ICU patients compared to non-ICU patients. The investigators will determine fluconazole and free fluconazole concentrations in 20 ICU patients, who will get intravenous fluconazole as standard care. Switching to oral/enteral fluconazol is allowed after day 3. A full pharmacokinetic curve will be taken on day 3 of iv therapy and limited pharmacokinetic curves on day 7 of iv therapy and/or on day 3 of oral therapy; trough levels will be taken daily after intravenous therapy.
Full Title of Study: “Pharmacokinetics of Fluconazole Given Intravenously as Prophylaxis or Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit (PACIFIC)”
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: March 2016
The pharmacokinetics of fluconazole are expected to be different in ICU patients compared to non-ICU patients and healthy volunteers due to underlying disease(s). Therefore, extrapolation of data from healthy volunteers and non-ICU patients is not possible. To be able to include 20 patients within the study duration, a multi-centre approach is necessary. Patients will receive standard care, as stated in the product characteristics or according to local protocols. Blood sampling for pharmacokinetic analysis will be retrieved through a central venous catheter. A maximum of 62 milliliter blood in total will be drawn for this study. Patients will be monitored daily during the treatment period for adverse events of the study drug. Full pharmacokinetic curves will be taken on day 3 of iv therapy. Limited pharmacokinetic curves will be taken on day 7 of iv therapy. These two moments of pharmacokinetic analysis will enable the determination steady state and enable the determination of intra-individual variability. As probably not all patients included will be treated with iv fluconazole for 7 days, switching to oral/enteral therapy is allowed after day 3. To assess bioavailability limited pharmacokinetic curves will be taken on day 3 of oral/enteral therapy.
- Drug: fluconazole
- Dose according to summary of product characteristics (SPC) or local protocols
Clinical Trial Outcome Measures
- Area under the curve
- Time Frame: Days 3 and 7
- Full pharmacokinetic curves will be taken op Day 3 and Day 7 (fluconazole).
- body weight
- Time Frame: Days 3 and 7
- Identifying influence of body weight on the pharmacokinetics of fluconazole.
Participating in This Clinical Trial
1. Patient is admitted to an ICU 2. Subject is at least 18 years of age on the day of the first dosing 3. Subject is managed with a central venous or arterial catheter Exclusion Criteria:
1. Is known to be hypersensitive to azole antifungal agents 2. Documented history of sensitivity to medicinal products or excipients similar to those found in the fluconazole preparation 3. Has previously participated in this trial
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Radboud University Medical Center
- Provider of Information About this Clinical Study
- Overall Official(s)
- Roger Brüggemann, PharmD, PhD, Principal Investigator, Radboud University Medical Center
Citations Reporting on Results
Muilwijk EW, de Lange DW, Schouten JA, Wasmann RE, Ter Heine R, Burger DM, Colbers A, Haas PJ, Verweij PE, Pickkers P, Brüggemann RJ. Suboptimal Dosing of Fluconazole in Critically Ill Patients: Time To Rethink Dosing. Antimicrob Agents Chemother. 2020 Sep 21;64(10). pii: e00984-20. doi: 10.1128/AAC.00984-20. Print 2020 Sep 21.
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.